BMRN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioMarin Pharmaceutical Inc (BMRN) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the company has potential catalysts such as the Amicus acquisition and Voxzogo expansion, the financial performance is weak with declining net income and EPS. Additionally, technical indicators show a bearish trend, and there are no strong trading signals or recent news to suggest a significant upward movement in the near term. A hold position is recommended until clearer positive signals emerge.
The technical indicators show a bearish trend with moving averages in a downward pattern (SMA_200 > SMA_20 > SMA_5). The RSI is neutral at 34.229, and the MACD histogram is slightly positive but contracting. The stock is trading near its support level (S1: 54.189), but no clear breakout or reversal signals are present.
Potential catalysts include the Amicus acquisition and Voxzogo indication expansion, which analysts view as key value drivers. Analyst ratings remain largely positive, with several buy and outperform ratings.
Financial performance is a concern with a significant drop in net income (-137.28% YoY) and EPS (-137.50% YoY). Competitive headwinds for Voxzogo and the discontinuation of Roctavian also pose risks. Technical indicators are bearish, and there are no recent news or significant trading trends to support a buy decision.
In Q4 2025, revenue increased by 17.03% YoY to $874.57M, but net income dropped significantly to -$46.57M (-137.28% YoY). EPS also declined to -$0.24 (-137.50% YoY). Gross margin improved slightly to 81.55% (+1.32% YoY), but overall profitability metrics are weak.
Analysts have mixed views. While several firms maintain buy or outperform ratings with price targets ranging from $75 to $105, some have lowered their targets due to competitive pressures and conservative assumptions. The average price target is significantly above the current price, but near-term risks remain.
